Clinical Trial Search

Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331

Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)

Primary: Change in Left Ventricular Systolic Function. — .82; -1.90 percent LVEF — p=.14

Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients

Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…

Primary: Peak Oxygen Uptake — 15 ml/kg/min

Primary: Number of Participants With Acute Procedural Success (APS) — 27 Participants

Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47

Primary: Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS). — 0.068; 0.259; -0.179; 0.100 PCr /…

Primary: Myocardial Perfusion Reserve — 1.52; 1.94 arbitrary units

Primary: Cardiac Glucose Uptake During Normoxic Rest (µg/Min) — 0.689; 0.540 µg/min — p=0.38

Primary: Cardiac Function: Duration of Apnea — 483 sec

Primary: Change in Cardiac Function: LVEF — 36.14; 36.11; 40.59 LVEF Percentage — p=0.063

Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants

Primary: Left Ventricular Global Longitudinal Strain (LVGLS) — 16.6; 16.4 % of LVGLS

Primary: Cardiac Ejection Fraction — 64; 66; 65; 62 Percent

Primary: LAERP (Left Atrial Effective Refractory Period (ie, the Longest S1-S2 Interval That Fails to Result in Atrial Depolarisation)) — 11; 43; 55; 50 ms

Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…

Primary: Reduction of the Left Ventricular Filling Pressure in Association With Administration of Sildenafil — 16.7; 16.4 E/e' ratio

Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants

Primary: Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography — -18.36; -20.81 mL/m^2

Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04

Primary: esCCO (Estimated Continuous Cardiac Output) Monitor — 5.6 liters/minute

Primary: Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test — 488.1; 464.8; 394.0 meters

Primary: Changes in RV Function — 7.56 percentage

Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min

Primary: Number of Patients Detected With Ventricular Dysfunction, Pericardial Effusion, Valvular Disorders, Septal Disorders, and Coronary Anomalies. — 13; 13; 9; 4 Participants

Primary: Peak Vo2 — 33; 12.5 ml/kg/min

Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001

Primary: Establishment of a Dataset to Create an Algorithm to Measure Cardiac Output — 75; 2 Participants